Davis's Drug Guide
** Update Information **
Latest Update
This resource was last updated on:2019-7-24
New topics:
- abaloparatide
- amlodipine/celecoxib
- apalutamide
- avatrombopag
- bictegravir/emtricitabine/tenofovir alafenamide
- burosumab
- cerliponase alfa
- encorafenib
- erenumab
- lamivudine/tenofovir disoproxil fumarate
- lofexidine
- sodium zirconium cyclosilicate
- tildrakizumab
Changed topics:
- acalabrutinib
- adapalene
- angiotensin II
- apixaban
- ARIPiprazole
- atezolizumab
- avelumab
- belimumab
- benralizumab
- benznidazole
- bevacizumab
- calcium acetate
- calcium citrate
- captopril
- carfilzomib
- cariprazine
- carteolol
- copanlisib
- darunavir/cobicistat
- daunorubicin/cytarabine liposomal
- defibrotide
- deflazacort
- deutetrabenazine
- dexlansoprazole
- doxycycline†
- dupilumab
- durvalumab
- elbasvir/grazoprevir
- eluxadoline
- ephedrine
- ertugliflozin
- eteplirsen
- fentaNYL (transdermal)
- ferric pyrophosphate citrate
- fingolimod
- flupentixol
- fluticasone/umeclidinium/vilanterol
- fulvestrant
- gabapentin
- glycopyrrolate, oral inhalation
- glycopyrrolate/formoterol
- golimumab
- guselkumab
- hydrogen peroxide
- hydroxyurea
- ibrutinib
- ibuprofen
- imatinib
- indacaterol/glycopyrrolate
- inFLIXimab
- inotuzumab ozogamicin
- insulin aspart
- insulin degludec
- insulin glargine
- insulin glargine/lixisenatide
- insulin lispro, rDNA origin
- letermovir
- lovage
- macimorelin
- mechlorethamine
- methIMAzole
- mipomersen
- naloxegol
- natalizumab
- niCARdipine
- nilotinib
- nintedanib
- nivolumab
- nusinersen
- obeticholic acid
- obiltoxaximab
- obinutuzumab
- olaparib
- olaratumab
- omacetaxine
- ombitasvir/paritaprevir/ritonavir
- ombitasvir/paritaprevir/ritonavir/dasabuvir
- onabotulinumtoxinA
- osimertinib
- OXcarbazepine
- ozenoxacin
- palbociclib
- paliperidone
- pantoprazole
- PAZOPanib
- pembrolizumab
- PENTobarbital
- peramivir
- perampanel
- phytonadione
- pioglitazone
- PONATinib
- posaconazole
- prasterone
- prasugrel
- pregabalin
- RABEprazole
- raltegravir
- ranibizumab
- remifentanil
- rifAMPin
- rifAXIMin
- ritonavir
- rituximab/hyaluronidase
- rivaroxaban
- secnidazole
- semaglutide
- sodium sulfate/potassium sulfate/magnesium sulfate
- telotristat ethyl
- timolol†
- vestronidase alfa-vjbk
** Update Information ** is a sample topic from the Davis's Drug Guide.
To view other topics, please sign in or purchase a subscription.
Medicine Central™ is a quick-consult mobile and web resource that includes diagnosis, treatment, medications, and follow-up information on over 700 diseases and disorders, providing fast answers—anytime, anywhere. Complete Product Information.
Citation
Quiring, Courtney, et al. "** Update Information **" Davis's Drug Guide, 16th ed., F.A. Davis Company, 2019. Medicine Central, im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/50998/all/___Update_Information___.
Quiring C, Sanoski CA, Vallerand AH. ** Update Information ** Davis's Drug Guide. 16th ed. F.A. Davis Company; 2019. https://im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/50998/all/___Update_Information___. Accessed October 16, 2019.
Quiring, C., Sanoski, C. A., & Vallerand, A. H. (2019). ** Update Information ** In Davis's Drug Guide. Available from https://im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/50998/all/___Update_Information___
Quiring C, Sanoski CA, Vallerand AH. ** Update Information ** [Internet]. In: Davis's Drug Guide. F.A. Davis Company; 2019. [cited 2019 October 16]. Available from: https://im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/50998/all/___Update_Information___.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - ** Update Information **
ID - 50998
A1 - Quiring,Courtney,
AU - Sanoski,Cynthia A,
AU - Vallerand,April Hazard,
BT - Davis's Drug Guide
UR - https://im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/50998/all/___Update_Information___
PB - F.A. Davis Company
ET - 16
DB - Medicine Central
DP - Unbound Medicine
ER -